GPT-5.5 in Rachel Environment Closes 111 of 120 PaRoutes Targets via Stateful Retrosynthetic Revision

The arXiv preprint describes Rachel as an open execution layer that validates each proposed disconnection against chemoselectivity and precursor availability rather than imposing search heuristics. GPT-5.5 maintained route coherence across multi-step revisions, outperforming fixed-policy baselines that dropped to 6-15 closures. Forward-model support on a shared subset exceeded most published comparators, and blinded LLM evaluators assigned Rachel the highest mean route score. This demonstrates that general-purpose models can sustain strategic adjustments when earlier choices alter downstream constraints, a capability previously assumed to require specialized planners. Pharmaceutical route design often stalls at chemoselectivity bottlenecks that force redesigns; Rachel-style coordination could compress the typical 6-12 month planning phase for complex APIs by surfacing viable alternatives earlier. Prior work such as Segler et al. (Nature 2018) relied on template-augmented Monte Carlo search, while recent LLM retrosynthesis papers still funnel outputs through external validators; Rachel removes that scaffold yet retains high closure rates. The RF25 cohort's post-cutoff provenance strengthens claims of genuine planning rather than memorization. Industrial adoption will hinge on integration with validated forward predictors and scale-up feasibility checks. A 500-compound internal benchmark at a mid-size pharma firm showing equivalent closure above 85 percent would accelerate deployment within 18 months.